Physician profile
Andrew G Hicks
NPI 1154757995
$459,965.10
in general payments reported to CMS, 2019-2025
32 companies · $233K in 2025
The $233K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $21K · 2023: $63K · 2024: $129K · 2025: $233K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $304K · Travel and Lodging: $59K · Consulting Fee: $27K · Food and Beverage: $24K · Honoraria: $9,900 · Education: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $304,089.00 |
| Travel and Lodging | $59,177.08 |
| Consulting Fee | $26,913.00 |
| Food and Beverage | $24,298.09 |
| Honoraria | $9,900.00 |
| Education | $607.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $184,243.48 | 2021-2025 | Ebglyss, Olumiant, Taltz |
| Janssen Biotech, INC. | $173,024.21 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $43,198.67 | 2021-2025 | Bimzelx, Cimzia |
| Botanix Sb INC | $21,704.56 | 2025 | Sofdra |
| Organon LLC | $13,528.96 | 2025 | Vtama |
| Eli Lilly and Company | $3,971.35 | 2025 | Ebglyss |
| Sun Pharmaceutical Industries INC. | $3,154.97 | 2021-2025 | Ilumya, Winlevi, Odomzo |
| Abbvie INC. | $3,025.41 | 2021-2025 | |
| Dermavant Sciences, INC. | $2,250.33 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $1,901.98 | 2022-2025 | Sotyktu |
| Amgen INC. | $1,315.86 | 2022-2025 | Otezla, Enbrel, Otezla |
| Leo Pharma INC. | $1,257.55 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $1,080.25 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,020.54 | 2021-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $1,012.19 | 2023-2025 | Zoryve |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $939.64 | 2022-2023 | Spevigo |
| Novartis Pharmaceuticals Corporation | $856.03 | 2021-2025 | |
| Pfizer INC. | $654.67 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $608.74 | 2021-2025 | Jublia, Duobrii, Siliq |
| Galderma Laboratories, L.P. | $543.96 | 2021-2025 | Nemluvio, Aklief |
| Incyte Corporation | $220.59 | 2022-2025 | Opzelura |
| Allergan, INC. | $104.60 | 2021-2022 | |
| Genentech USA, INC. | $83.46 | 2025 | Xolair |
| Springworks Therapeutics, INC. | $58.13 | 2025 | Gomekli |
| Almirall LLC | $45.71 | 2021-2025 | Klisyri |
| Mayne Pharma Commercial LLC | $35.42 | 2023-2025 | |
| Kyowa Kirin, INC. | $25.69 | 2024 | Poteligeo |
| Biocon Biologics INC | $23.19 | 2024 | Hulio |
| Verrica Pharmaceuticals INC. | $20.11 | 2023 | Ycanth |
| Fidia Pharma USA INC. | $19.68 | 2025 | |
| Organogenesis INC. | $18.86 | 2025 | Puraply Wound Matrix |
| Epi Health, LLC | $16.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.